Expert Consensus Score
GLP-1 Agonists
Moderate Consensus
out of 5
Based on 61 videos across 5 experts · Updated 2026-03-19
Expert Positions
The Verdict
This is one of the most polarizing topics across our expert panel. Attia and Huberman see GLP-1 agonists as powerful tools when combined with exercise and high protein intake, while Hyman strongly opposes their widespread use, arguing they mask root causes and create pharmaceutical dependency. This is a prescription medication, not a supplement — use requires physician oversight.
Quick Protocol
Dosage
Semaglutide: typically starts at 0.25mg/week, titrated up to 2.4mg/week for weight management. Tirzepatide: starts at 2.5mg/week, titrated up to 15mg/week. Dosing is individualized by a prescribing physician (Attia).
Form
Injectable (subcutaneous, once weekly). Oral formulations are in development. Some clinicians use compounded peptide formulations at lower doses (Attia, Koniver).
Timing
Once-weekly injection. No specific time-of-day requirement. Must be combined with strength training and high protein intake (minimum 1g per pound of lean body mass) to mitigate muscle loss (Attia).
Key Findings
- GLP-1 agonists work through multiple mechanisms: suppressing appetite via brain satiety centers, slowing gastric emptying, improving insulin secretion, and reducing hepatic glucose production (Attia).
- Semaglutide is a pure GLP-1 agonist (Ozempic for diabetes, Wegovy for obesity), while tirzepatide is a dual GIP/GLP-1 co-agonist (Mounjaro) with higher potency for weight loss (Attia).
- The most significant risk is lean muscle mass loss — Attia calls the rate 'alarming' and insists patients must combine GLP-1 use with high protein intake and rigorous strength training, monitored via DEXA scans.
- Weight regain upon discontinuation is common. Attia advises these drugs are best used indefinitely, with lifestyle changes adopted during use improving chances of maintaining weight loss if stopped.
+ 4 more findings in the full report
Read the Full GLP-1 Agonists Report
Expert deep dives, video citations with timestamps, risks, synergies, and detailed protocol.
View Full Report